Keshvani Neil, Rizvi Syed, Segar Matthew W, Miller James W, Coellar Juan David, Patel Kershaw V, Roehm Bethany, Tang W H Wilson, Pandey Ambarish
Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Department of Cardiology, Texas Heart Institute, Houston, TX, USA.
Eur J Heart Fail. 2025 Feb;27(2):347-352. doi: 10.1002/ejhf.3537. Epub 2024 Dec 2.
Diuretic resistance (DR) in heart failure (HF) is associated with worse outcomes. Furoscix®, a self-administered subcutaneous (sc) furosemide injection administered via on-body infusor, is approved for HF congestion relief. However, its efficacy in patients with DR post-HF hospitalization remains unknown.
In this open-label pilot randomized controlled trial, 70 participants were randomized within 14 days post-HF hospitalization to receive a single dose of 80 mg sc furosemide or home oral dose furosemide. Enrolment was stratified by presence of DR (admission BAN-ADHF score ≥12) with a 2:1 enrolment of those with versus without DR. Key outcomes included diuretic efficiency, the total urine output per mg of diuretic administered, and peak urine sodium within 8 h of dose administration. Treatment effects were calculated as the difference in estimated marginal means across study groups and DR strata using linear mixed-effect models. Overall, 70 participants were enrolled (57 years, 27% female, 70% Black, 79% with HF with reduced ejection fraction). Participants with DR (n = 46) had worse kidney function, higher N-terminal pro-B-type natriuretic peptide, and higher home diuretic dose. Among participants with DR, sc furosemide versus oral furosemide led to significantly greater diuretic efficiency (34.0 vs. 22.6 ml/mg, p = 0.002) and peak urine sodium (100 vs. 83 mmol/L, p = 0.029), while participants without DR had similar diuretic efficiency (29.8 vs. 30.1 ml/mg, p = 0.94) and peak urine sodium (96 vs. 95 mmol/L, p = 0.93) across both treatments. DR significantly modified the effect of sc versus oral furosemide on diuretic efficiency (p: treatment × diuretic resistance = 0.022).
Single-dose sc furosemide was associated with greater diuretic efficiency and peak urine sodium than oral furosemide in participants with DR discharged following recent HF hospitalization.
心力衰竭(HF)中的利尿剂抵抗(DR)与更差的预后相关。Furoscix®是一种通过体内输注器自行皮下(sc)注射的速尿,已被批准用于缓解HF充血。然而,其在HF住院后DR患者中的疗效尚不清楚。
在这项开放标签的试点随机对照试验中,70名参与者在HF住院后14天内被随机分组,接受单剂量80mg sc速尿或家庭口服速尿剂量。根据DR的存在情况(入院BAN-ADHF评分≥12)进行分层入组,DR患者与非DR患者的入组比例为2:1。主要结局包括利尿效率、每毫克利尿剂给药后的总尿量以及给药后8小时内的尿钠峰值。使用线性混合效应模型计算各研究组和DR分层之间估计边际均值的差异作为治疗效果。总体而言,共纳入70名参与者(年龄57岁,27%为女性,70%为黑人,79%为射血分数降低的HF患者)。DR患者(n = 46)的肾功能更差,N末端B型利钠肽更高,家庭利尿剂剂量更高。在DR患者中,sc速尿与口服速尿相比,利尿效率显著更高(34.0对22.6ml/mg,p = 0.002),尿钠峰值更高(100对83mmol/L,p = 0.029),而在非DR患者中,两种治疗的利尿效率相似(29.8对30.1ml/mg,p = 0.94),尿钠峰值相似(96对95mmol/L,p = 0.93)。DR显著改变了sc速尿与口服速尿对利尿效率的影响(p:治疗×利尿剂抵抗 = 0.022)。
在近期HF住院后出院的DR参与者中,单剂量sc速尿比口服速尿具有更高的利尿效率和尿钠峰值。